(Circulation. 1999;99:475-481.)
© 1999 American Heart Association, Inc.
Clinical Investigation and Reports |
Delayed Response of Myocardial Flow Reserve to Lipid-Lowering Therapy With Fluvastatin
From Abteilung für Kardiologie, Klinikum München-Bogenhausen (M.G., A.M.K., K.C., W.D.) and Nuklearmedizinische Klinik der Technischen Universität München (S.Z., M.S.), München, Germany.
Correspondence to M. Schwaiger, MD, Nuklearmedizinische Klinik, Technische Universität München, Ismaninger Straße 22, 81675 München, Germany. E-mail m.schwaiger{at}lrz.tu-muenchen.de
Background—Lipid-lowering therapy can improve endothelial function in patients with coronary artery disease (CAD) and hypercholesterolemia. Little is known about induced changes in myocardial microcirculation. This study prospectively investigated the temporal effects of lipid-lowering therapy with fluvastatin on coronary flow and flow reserve (CFR) in patients with CAD assessed by PET.
Methods and Results—In an open clinical trial, CFR was studied in 15 patients with angiographically documented multivessel CAD and hypercholesterolemia (LDL >160 mg/dL). Dynamic 13N-labeled ammonia PET imaging in conjunction with adenosine was used to assess regional and global CFR at baseline as well as at 2 and 6 months during treatment with fluvastatin (60 to 80 mg/d). Despite a rapid decrease in total cholesterol (29±6%) and LDL (37±9%), myocardial blood flow at rest and during stress was unchanged after 2 months of treatment (2.7±0.9 versus 2.5±0.6 mL · g-1 · min-1). At 6 months, stress blood flow as well as CFR increased significantly (3.4±1.0 mL · g-1 · min-1). No change in hemodynamic parameters was noted during the entire study. Nine of 15 patients increased CFR by >20%. All responders demonstrated improvement in anginal symptoms, whereas nonresponders stated no change (n=4) or worsening of symptoms (n=2). The improvement in CFR was not related to the amount of lipid lowering and was independent of the severity of stenoses.
Conclusions—Improvement in stress blood flow and CFR is delayed compared with the lipid-lowering effect of fluvastatin, suggesting a slow recovery of the vasodilatory response to adenosine.
Key Words: lipids • fluvastatin • blood flow • PET • adenosine
This article has been cited by other articles:
 |
|
 |
|
  M. R. Vesely and V. Dilsizian Nuclear Cardiac Stress Testing in the Era of Molecular Medicine J. Nucl. Med., March 1, 2008; 49(3): 399 - 413. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J Knuuti and F M Bengel Positron emission tomography and molecular imaging Heart, March 1, 2008; 94(3): 360 - 367. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Morita, T. Tsukamoto, M. Naya, K. Noriyasu, M. Inubushi, T. Shiga, C. Katoh, Y. Kuge, H. Tsutsui, and N. Tamaki Smoking Cessation Normalizes Coronary Endothelial Vasomotor Response Assessed with 15O-Water and PET in Healthy Young Smokers J. Nucl. Med., December 1, 2006; 47(12): 1914 - 1920. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. van der Harst, A. A. Voors, W. H. van Gilst, M. Bohm, and D. J. van Veldhuisen Statins in the treatment of chronic heart failure: Biological and clinical considerations Cardiovasc Res, August 1, 2006; 71(3): 443 - 454. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Schwaiger, S. Ziegler, and S. G. Nekolla PET/CT: Challenge for Nuclear Cardiology J. Nucl. Med., October 1, 2005; 46(10): 1664 - 1678. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. A. Kaufmann, M. Namdar, F. Matthew, M. Roffi, S. V. Aschkenasy, B. van der Loo, G. Sutsch, T. F. Luscher, and R. Jenni Novel Doppler Assessment of Intracoronary Volumetric Flow Reserve: Validation Against PET in Patients With or Without Flow-Dependent Vasodilation J. Nucl. Med., August 1, 2005; 46(8): 1272 - 1277. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. T. McMahon, J. Plutzky, E. Daher, T. Bhattacharyya, G. Grunberger, and M. F. DiCarli Effect of a Peroxisome Proliferator-Activated Receptor-{gamma} Agonist on Myocardial Blood Flow in Type 2 Diabetes Diabetes Care, May 1, 2005; 28(5): 1145 - 1150. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. A. Kaufmann and P. G. Camici Myocardial Blood Flow Measurement by PET: Technical Aspects and Clinical Applications J. Nucl. Med., January 1, 2005; 46(1): 75 - 88. [Full Text] [PDF]
|
|
|
|
 |
|
 I. Yokoyama, Y. Inoue, T. Moritan, K. Ohtomo, and R. Nagai Impaired myocardial vasodilatation during hyperaemic stress is improved by simvastatin but not by pravastatin in patients with hypercholesterolaemia Eur. Heart J., April 2, 2004; 25(8): 671 - 679. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. G. Schwartz, T. A. Pearson, V. G. Kalaria, M. L. Mackin, D. J. Williford, A. Awasthi, A. Shah, A. Rains, and J. J. Guido Prospective serial evaluation of myocardial perfusion and lipids during the first six months of pravastatin therapy: Coronary artery disease regression single photon emission computed tomography monitoring trial J. Am. Coll. Cardiol., August 20, 2003; 42(4): 600 - 610. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. A. Schmidt, A. Chakrabarti, Q. Shamim-Uzzaman, N. Kaciroti, R. A. Koeppe, and S. Rajagopalan Calf Flow Reserve with H215O PET as a Quantifiable Index of Lower Extremity Flow J. Nucl. Med., June 1, 2003; 44(6): 915 - 919. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. A. Wyss, P. Koepfli, K. Mikolajczyk, C. Burger, G. K. von Schulthess, and P. A. Kaufmann Bicycle Exercise Stress in PET for Assessment of Coronary Flow Reserve: Repeatability and Comparison with Adenosine Stress J. Nucl. Med., February 1, 2003; 44(2): 146 - 154. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A.H Liem, A.J van Boven, N.J.G.M Veeger, A.J Withagen, R.M Robles de Medina, J.G.P Tijssen, and D.J van Veldhuisen Effect of fluvastatin on ischaemia following acute myocardial infarction: a randomized trial Eur. Heart J., December 2, 2002; 23(24): 1931 - 1937. [Abstract] [PDF]
|
|
|
|
 |
|
 M. Hernandez-Pampaloni, F. Y.J. Keng, T. Kudo, J. S. Sayre, and H. R. Schelbert Abnormal Longitudinal, Base-to-Apex Myocardial Perfusion Gradient by Quantitative Blood Flow Measurements in Patients With Coronary Risk Factors Circulation, July 31, 2001; 104(5): 527 - 532. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. Tamaki, Y. Kuge, and E. Tsukamoto The Road to Quantitation of Regional Myocardial Uptake of Tracer J. Nucl. Med., May 1, 2001; 42(5): 780 - 781. [Full Text]
|
|
|
|
|
|
P. A. Kaufmann, T. Gnecchi-Ruscone, M. di Terlizzi, K. P. Schafers, T. F. Luscher, and P. G. Camici Coronary Heart Disease in Smokers : Vitamin C Restores Coronary Microcirculatory Function Circulation, September 12, 2000; 102(11): 1233 - 1238. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. A. Kaufmann, T. Gnecchi-Ruscone, K. P. Schafers, T. F. Luscher, and P. G. Camici Low density lipoprotein cholesterol and coronary microvascular dysfunction in hypercholesterolemia J. Am. Coll. Cardiol., July 1, 2000; 36(1): 103 - 109. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Corsini Reviews: Fluvastatin: Effects Beyond Cholesterol Lowering Journal of Cardiovascular Pharmacology and Therapeutics, January 1, 2000; 5(3): 161 - 175. [Abstract] [PDF]
|
|
|
|
 |
|
 T. W. Hein, J. C. Liao, and L. Kuo oxLDL specifically impairs endothelium-dependent, NO-mediated dilation of coronary arterioles Am J Physiol Heart Circ Physiol, January 1, 2000; 278(1): H175 - H183. [Abstract] [Full Text] [PDF]
|
|